<DOC>
	<DOCNO>NCT01021891</DOCNO>
	<brief_summary>Trial include 40 subject consist 3 visit : Screening , Treatment Follow . A euglycemic clamp procedure Technosphere速/Insulin ( T/I ) administration occur Visit 2 COPD non COPD subject .</brief_summary>
	<brief_title>A Study Evaluate Insulin Blood After Inhalation Dry Powder Insulin Formulation ( Called Technosphere速/Insulin ) Non-diabetic Patients With &amp; Without Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Trial objective evaluate impact define lung disease ( COPD ) pharmacokinetic parameter insulin fumaryl diketopiperazine ( FDKP ) inhalation Technosphere速/Insulin ( T/I ) , investigational medicinal product . 40 non diabetic subject , 20 COPD 20 age/gender/BMI-matched non COPD subject participate 3 visit : Visit 1 ( screen ) , Visit 2 ( subject undergo euglycemic clamp procedure dose T/I ) Visit 3 ( follow visit ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female subject minimum 18 maximum 70 year age Body Mass Index ( BMI ) = 36 kg/m2 Subjects COPD : Diagnosis COPD ( emphysema and/or chronic bronchitis ) , smoke history =10 year , chronic cough present intermittently daily without sputum and/or dyspnea upon exertion . Subjects COPD : Pulmonary Function Tests FEV1 =50 % ( NHANES ) III Predicted ; FEV1/FVC &lt; 70 % ( NHANES ) III ; TLC =80 % Predicted ( ITS ) DLco ( unc ) =50 % Predicted ( Miller ) Subjects without COPD : PFTs : FEV1 = 70 % NHANES III Predicted ; TLC =80 % Predicted ( ITS ) DLco ( unc ) =80 % Predicted ( Miller ) History prediabetes diabetes Previous current treatment antidiabetic drug Serum creatinine &gt; 2.0 mg/dL male &gt; 1.8 mg/dL female Active smoker define smoke last cigarette , pipe , and/or cigar without previous 6 month Previous exposure inhale insulin product investigational medicines/devices within previous 30 day prior entry participation Clinically significant major organ disease Female subject childbearing potential practicing adequate birth control Subjects COPD : Significant improvement preto postbronchodilator spirometry ( defined increase 12 % AND 200 mL either FVC FEV1 ) ; Any clinically important pulmonary disease except mild moderate COPD Subjects without COPD : Any important pulmonary disease confirm pulmonary function test and/or radiologic finding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Technosphere速 Insulin Inhalation Powder</keyword>
</DOC>